Michelle Haber

Q: What Schools Are Affiliated With Michelle Haber

Michelle Haber is affiliated with the following schools: University of Sydney, University of New South Wales, University of Bologna

Michelle Haber's AcademicInfluence.com Rankings

Michelle Haber

Philosophy

#10560

World Rank

#14481

Historical Rank

Logic

#7547

World Rank

#9338

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Michelle Haber Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michelle Haber is an Australian cancer researcher. Haber is an Australian scientist in the field of childhood cancer research. She serves as the Executive Director of Children's Cancer Institute and is a professor at the School of Women’s and Children’s Health, University of New South Wales. She is known for her discoveries in the area of chemotherapy resistance in neuroblastoma and for translating these discoveries into new therapeutics that are currently in clinical trials.

(See a Problem?)

Michelle Haber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ABC transporters in cancer: more than just drug efflux pumps (2010) (926)
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. (1997) (600)
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee (2009) (330)
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. (1996) (310)
ABC transporters as mediators of drug resistance and contributors to cancer cell biology. (2016) (290)
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. (2004) (235)
Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. (2001) (219)
The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. (2002) (195)
Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer (2007) (194)
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma (2010) (192)
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. (2008) (192)
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. (2014) (177)
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. (1994) (176)
The p53 pathway and its inactivation in neuroblastoma. (2003) (169)
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. (2006) (165)
The histone deacetylase SIRT2 stabilizes Myc oncoproteins (2012) (162)
Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. (1998) (152)
SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability (2011) (145)
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. (2004) (144)
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro (2005) (141)
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project (2012) (141)
Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) (1995) (135)
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer (2020) (123)
ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux (2011) (119)
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis (2007) (115)
Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. (2003) (114)
Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His27 and Arg27 carriers (2001) (111)
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma (2015) (109)
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. (2000) (109)
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. (2007) (105)
The International Neuroblastoma Risk Groups (INRG): a preliminary report. (1997) (104)
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. (2003) (103)
The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression (2016) (101)
Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells* (2010) (95)
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. (2009) (95)
Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. (1989) (84)
Involvement of MDR1 P‐glycoprotein in multifactorial resistance to methotrexate (1996) (84)
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours (2019) (84)
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (82)
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma (2018) (81)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design (2019) (80)
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion (2020) (80)
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma (2004) (80)
Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring (2010) (75)
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells (1999) (75)
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. (2017) (74)
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma (2019) (73)
Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. (2017) (69)
Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. (2001) (68)
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. (2015) (67)
Too many targets, not enough patients: rethinking neuroblastoma clinical trials (2018) (66)
p53 determines multidrug sensitivity of childhood neuroblastoma. (2007) (64)
Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group (2017) (64)
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia (2015) (63)
Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. (2004) (62)
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. (1997) (60)
Testing of new agents in childhood cancer preclinical models: meeting summary. (2002) (60)
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation (2013) (59)
The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. (2014) (58)
Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation (2013) (58)
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells (2010) (58)
Favorable prognostic significance of high-level retinoic acid receptor β expression in neuroblastoma mediated by effects on cell cycle regulation (1998) (57)
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. (2013) (57)
Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. (2000) (55)
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression (2016) (54)
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. (2003) (54)
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35 (2019) (52)
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia (2009) (51)
The retinoid anticancer signal: mechanisms of target gene regulation (2005) (50)
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma (2019) (50)
Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell Differentiation* (2009) (50)
The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. (1997) (49)
High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). (2014) (48)
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. (1999) (48)
The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1 (2014) (48)
Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression (2009) (46)
A simple method for the isolation of genomic DNA from mouse tail free of real-time PCR inhibitors. (2002) (44)
c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells (2011) (44)
Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. (2020) (43)
Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. (2009) (42)
Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. (1997) (42)
GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis. (2014) (42)
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. (2007) (42)
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer (2008) (41)
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation (2013) (41)
Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia. (1995) (40)
Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma (2012) (40)
Molecular profiling of childhood cancer: Biomarkers and novel therapies (2014) (40)
Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. (2009) (40)
MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells (2001) (39)
High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. (2016) (39)
P‐glycoprotein‐mediated methotrexate resistance in CCRF‐CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene (1998) (38)
Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas (2021) (38)
Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. (2018) (38)
The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro (2011) (36)
Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. (1993) (36)
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth (2016) (35)
Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. (1995) (35)
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion (2011) (35)
Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. (2005) (34)
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer (2016) (34)
The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. (2009) (33)
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma. (2018) (33)
ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma (2012) (32)
Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate. (1989) (31)
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 (2014) (30)
Mechanism of relapse in pediatric acute lymphoblastic leukemia (2008) (30)
The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. (2005) (29)
Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma. (1997) (28)
The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal* (2006) (28)
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. (2016) (27)
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis (2019) (27)
High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance (2001) (27)
Enhancing the anti-angiogenic action of histone deacetylase inhibitors (2007) (27)
Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy (2020) (26)
ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells (2009) (26)
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B‐cell acute lymphoblastic leukaemia in children (2018) (25)
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis (2020) (25)
TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells (2013) (25)
Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. (2002) (25)
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia (2020) (24)
ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript (2011) (24)
Retinoic Acid Receptors β and γ Distinguish Retinoid Signals for Growth Inhibition and Neuritogenesis in Human Neuroblastoma Cells (1996) (24)
ABC transporters and neuroblastoma. (2015) (24)
Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma (2007) (24)
Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. (1993) (23)
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer (2014) (23)
Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma (2012) (22)
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. (2019) (22)
Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2) (2003) (22)
Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. (2003) (21)
Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells (2002) (21)
The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. (2009) (21)
Glutathione biosynthesis is upregulated at the initiation of MYCN‐driven neuroblastoma tumorigenesis (2016) (20)
Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers. (1995) (20)
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma (2015) (20)
Immune profiling of pediatric solid tumors. (2020) (20)
An unexpected role for caspase-2 in neuroblastoma (2014) (20)
Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines (2008) (20)
Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition (2020) (19)
HLA-G polymorphisms, genetic susceptibility, and clinical outcome in childhood neuroblastoma. (2011) (19)
Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real‐time polymerase chain reaction (2000) (19)
Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. (2001) (19)
Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. (2019) (19)
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. (2021) (18)
Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease (2013) (18)
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs (2016) (17)
Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue. (1994) (17)
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo. (2017) (17)
Folate Pathway Gene Polymorphisms, Maternal Folic Acid Use, and Risk of Childhood Acute Lymphoblastic Leukemia (2014) (17)
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression. (1989) (17)
Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines. (1993) (16)
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4 (2016) (15)
Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma (2012) (15)
Clinical Relevance of Multidrug-Resistance-Proteins (MRPs) for Anticancer Drug Resistance and Prognosis (2015) (15)
Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy (2020) (15)
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction (2019) (15)
Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. (1998) (15)
Growth inhibitory retinoid effects after recruitment of retinoid X receptor β to the retinoic acid receptor β promoter (2003) (15)
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer (2018) (15)
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. (2021) (15)
Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia (2008) (15)
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. (2012) (14)
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. (2009) (14)
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia (2021) (14)
Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. (2014) (14)
Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma (2015) (13)
Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia (2009) (13)
MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma (2015) (12)
Regions syntenic to human 17q are gained in mouse and rat neuroblastoma (2004) (12)
Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-κ and heavy-chain gene rearrangements (2008) (12)
Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoter. (2003) (12)
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia (2019) (12)
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T‐cell leukemia xenograft, LALW‐2 (1991) (11)
Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer (2018) (11)
Retinoic acid receptors beta and gamma distinguish retinoid signals for growth inhibition and neuritogenesis in human neuroblastoma cells. (1996) (11)
A xenograft model of infant leukaemia reveals a complex MLL translocation (2008) (11)
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements (2016) (10)
Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia (2016) (9)
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma (2021) (9)
The RNA‐helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma (2021) (9)
Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression (2020) (9)
Therapy‐induced drug resistance in a human leukemia line (LALW‐2) (1989) (9)
Expression of retinoic acid-responsive genes in primary neuroblastomas. (1994) (9)
Early-phenotype CAR-T cells for the treatment of pediatric cancers. (2021) (8)
ABCC4/MRP4 contributes to the aggressiveness of Myc‐associated epithelial ovarian cancer (2020) (8)
Single-strand-specific degradation of DNA during isolation of rat liver nuclei. (1985) (8)
miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia (2019) (8)
Synergy between 5′ and 3′ flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells (2000) (8)
Sizing of DNA fragments by preparative, benzoylated DEAE‐cellulose chromatography (1981) (8)
Patterns of structural change in DNA during tissue necrosis indicated by benzoylated DEAE-cellulose chromatography. (1985) (7)
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer (2021) (7)
MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma. (2018) (7)
Sensitive non‐radioactive PCR detection of clonal T‐cell receptor‐gamma gene rearrangements in childhood acute lymphoblastic leukaemia (1997) (7)
Limitations on the stability of benzoylated DEAE-cellulose. (1984) (7)
Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR. (2001) (7)
Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin (2021) (7)
N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction. (1994) (6)
Small Molecule MRP1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Model of Neuroblastoma (2009) (6)
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma (2021) (6)
Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study (2015) (6)
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma (2021) (6)
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma (2021) (6)
Dose-dependent persistence of alkylation-induced single stranded regions in rat liver DNA in vivo. (1985) (6)
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration. (1990) (6)
Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue. (1998) (5)
Pilot study of a comprehensive precision medicine platform for children with high-risk cancer. (2017) (5)
Oncogenes. A possible role for cancer genes in human malignant disease. (1985) (5)
Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors. (2021) (5)
The MYCN Oncogene (2013) (5)
Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer (2022) (5)
Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose. (1986) (5)
Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors (2021) (5)
Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine (2005) (5)
Methodological advances in the discovery of novel neuroblastoma therapeutics (2021) (4)
Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy (2021) (4)
Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors (2020) (4)
Donor T cells for CAR T cell therapy (2022) (4)
An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro. (1995) (4)
Abstract 2450: MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis (2016) (3)
Isolated testicular relapse after allo-SCT in boys with ALL: outcome without second transplant (2010) (3)
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer (2020) (3)
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma (2021) (3)
Characterization of Mechanisms Mediating Drug Resistance in Human Leukemic Cells Selected with High Concentration Methotrexate (1991) (3)
Targeting Multidrug Resistance in Neuroblastoma (2012) (3)
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression (2022) (3)
181 INVITED International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk grouping (INRG) biology committee (2007) (2)
Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling (2019) (2)
NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma. (2018) (2)
Analysis of a novel cDNA encoding a C219-reactive peptide isolated from methotrexate-selected multidrug-resistant human leukemic cells. (1995) (2)
Optimization of a clofarabine‐based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia (2019) (2)
Small Molecule Drugs and Targeted Therapies for Neuroblastoma (2012) (2)
Abstract 2759: Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-κB and activates p53, is highly effective in two independent mouse models of neuroblastoma. (2013) (2)
Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells (2015) (2)
Abstract LB-138: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer (2018) (2)
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors (2021) (2)
Abstract 1425: Prognostic significance of promoter DNA methylation in patients with neuroblastoma (2012) (2)
GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators (2021) (2)
Relapse in children with acute lymphoblastic leukaemia involving selection of a pre-existing drug resistant sub-clone Short title: Clonal selection and relapse in ALL (2007) (2)
Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours. (2001) (2)
Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer (2020) (2)
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma (2018) (1)
Abstract 51: Molecular profiling of relapsed childhood cancer (2016) (1)
Abstract 3111: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer (2019) (1)
Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy (2020) (1)
Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia (2022) (1)
In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells. (1998) (1)
MYCN interacts with histone deacetylase to modulate target gene transcription (2006) (1)
Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target (2018) (1)
Abstract 954: ABCC/MRP multidrug transporters contribute to neuroblastoma biology, pathogenesis and clinical outcome, independently of any role in cytotoxic drug efflux (2011) (1)
Reversan, a novel inhibitor of MRP1, increases the therapeutic index of conventional chemotherapeutic agents (2008) (1)
Abstract 2664: Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA (2016) (1)
Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
Optimization of theAntitumor Efficacy of a SyntheticMitochondrial Toxin by Increasing theResidence Time in the Cytosol (2009) (1)
Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL (2020) (1)
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma (2021) (1)
Abstract 5832: Overexpression of ODC1 is associated with poor outcome in childhood neuroblastoma and represents an important therapeutic target (2008) (1)
Epigenetic Elimination of Mixed-Lineage Leukemia Leukemic Stem Cells by a Potent Small Molecule PRC2 Inhibitor. (2012) (1)
Expression of the multidrug transporter genes ABCC1/MRP1, ABCC3/MRP3, and ABCC4/MRP4 are powerful predictors of clinical outcome in childhood neuroblastoma (2007) (1)
Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma (2016) (1)
422 CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastoma (2014) (1)
The important role of routine cytopathology in pediatric precision oncology (2021) (1)
CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. (2019) (1)
The cyclin-dependent kinase inhibitor, p21WAF1, is a resistance factor for histone deacetylase inhibitors, and induces angiogenesis via the thioredoxin pathway (2007) (0)
Abstract PR09: MYCN and is a therapeutic target in neuroblastoma (2015) (0)
Corrigendum to: "MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma" [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235-245]. (2020) (0)
ACRF Drug Discovery Centre for Childhood Cancer: servicing cancer drug discovery (2012) (0)
DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION (2020) (0)
Abstract B23: Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening (2016) (0)
PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia (2018) (0)
252A ORAL Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone (2006) (0)
Inhibition of ABCC4 sensitises neuroblastoma cells to retinoic acid treatment (2012) (0)
Abstract 3044: The unexplored immune landscape of high-risk pediatric cancers (2021) (0)
Abstract 68: Beyond GWAS: The prognostic significance of promoter DNA methylation in patients with neuroblastoma. (2012) (0)
MYCN Expression I s N ot P rognostic o f A dverse O utcome i n Advanced-Stage N euroblastoma W ith N onamplified MYCN (2000) (0)
Cell-based methods for the identification of MYC-inhibitory small molecules. (2013) (0)
Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy (2012) (0)
Abstract 1175: Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia (2017) (0)
Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma (2020) (0)
Abstract 5138: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 (2014) (0)
Targeting RSPO3-LGR4Sig naling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia (2020) (0)
DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) (2020) (0)
Abstract 5237: Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization (2011) (0)
THER-23. RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRATED PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS (2019) (0)
Abstract SY09-02: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia (2020) (0)
Single Nucleotide Polymorphisms in the Human Reduced Folate Carrier: Characterization of a High-Frequency G/A Variant at Position 80 and Transport Properties of the His 27 and Arg 27 Carriers 1 (2001) (0)
Abstract 1834: Targeting ABC transporters in cancer through small molecule inhibitors (2012) (0)
The value of monitoring for MRD at late timepoints in paediatric all treatment (2011) (0)
Abstract 1956: ABCE1 regulates the translational profile of neuroblastoma to drive tumor progression (2017) (0)
TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells (2013) (0)
Abstract 3809: Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells (2019) (0)
Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies (2019) (0)
Abstract 5043: The facilitates chromatin transcription (FACT) protein complex promotes neuroblastoma tumor initiation. (2013) (0)
Abstract LB-367: New evidence supports the potential use of methotrexate in children with MYCN-amplified neuroblastoma. (2011) (0)
Scientific Section Heading: Neoplasia (2004) (0)
PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia (2018) (0)
DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM (2020) (0)
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes (2023) (0)
Abstract 4679: A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer (2011) (0)
169 POSTER Sensitisation of neuroblastoma tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor (2006) (0)
Abstract 2006: AMX-513 polyamine depletion therapy inhibits tumor growth and reverses immunosuppression in cancers including MYC-driven neuroblastoma and pancreatic cancer (2017) (0)
Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies (2020) (0)
Full-length tissue transglutaminase is a resistance factor for cell differentiation in neuroblastoma (2008) (0)
Selective Sensitization of murine tumors to chemotherapy by a novel class of non-toxic small molecule inhibitors of MRP1 (2006) (0)
Expression of GAGE genes in neuroblastoma by reverse transcription - Polymerase chain reaction (2001) (0)
Abstract 488: High DKC1 expression supports neuroblastoma tumor cell proliferation and is strongly associated with poor patient outcomes (2015) (0)
Abstract IA24: Targeting MYCN-driven neuroblastoma using novel therapeutic approaches (2014) (0)
Abstract 962: PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability (2015) (0)
Abstract 4800: Targeting the polyamine pathway as a novel therapeutic treatment against diffuse intrinsic pontine glioma (2018) (0)
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer (2022) (0)
Donor T cells for CAR T cell therapy (2022) (0)
Cell-Based Methods for the Identification of Myc-Inhibitory Small Molecules. (2021) (0)
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors (2022) (0)
Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy (2012) (0)
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma (2023) (0)
Digestion of repair sites in rat liver DNA by endogenous nucleases. (1986) (0)
Embryonal cancer initiation: MYCN-mediated mechanisms of resistance to cell death causing embryonal cell persistence (2007) (0)
Abstract 4883: Targeting tumor-amplifiedODC1with difluoromethylornithine (DFMO) inhibits global protein translation and has antitumor activity in neuroblastoma (2017) (0)
Abstract 2453: Eradication of neuroblastoma by suppressing the expression of a single noncoding RNA (2018) (0)
Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma (2019) (0)
Pre-clinical evaluation of the potential benefit of histone deacetylase inhibitor therapy for high-risk neuroblastoma in transgenic mice model (2004) (0)
Abstract 2616: A novel iron-chelating agent reduces MYC transcription via E2F gene family regulation (2019) (0)
Abstract 789: GSTP1 expression is regulated by MycN and is a marker of poor outcome in childhood neuroblastoma (2012) (0)
Importance o f M inimal R esidual D isease T esting D uring t he Second Y ear o f T herapy f or C hildren W ith A cute Lymphoblastic L eukemia (2003) (0)
De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision (2022) (0)
Abstract 313: Examining the role of ABCA1 cholesterol transporter in ovarian cancer spheroids (2015) (0)
International consensus for neuroblastoma molecular diagnostics: Report from the international neuroblastoma risk grouping (INRG) Biology committee (2009) (0)
Too many targets, not enough patients: rethinking neuroblastoma clinical trials (2018) (0)
Abstract 4056: A modulator of multidrug resistance protein 1 selectively depletes glutathione and synergizes with L-buthionine sulfoximine to sensitize MRP1-expressing cancer cells to chemotherapy (2017) (0)
Advances and Challenges in Pediatric and Childhood Cancers. (2020) (0)
ACRF Drug discovery centre for childhood cancer (2011) (0)
Dual Targeting of the Epigenome Via Facilitates Chromatin Transcription Complex (FACT) and Histone Deacetylase is a Potent Treatment Strategy for DIPG (2020) (0)
DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (2020) (0)
Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting (2015) (0)
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma (2021) (0)
The ornithine decarboxylase G316A promoter polymorphism impacts neuroblastoma clinical outcome and may identify patients particularly susceptible to polyamine inhibition (2018) (0)
The role of the estrogen-responsive B box protein (EBBP) in cancer cell cycle progression (2008) (0)
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours (2019) (0)
Oncogenes (1985) (0)
Chemotherapy in Mouse Models of Neuroblastoma Inhibitor Reversan Increases the Therapeutic Index of Associated Protein 1 − Small-Molecule Multidrug Resistance (2009) (0)
RARE-02. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (2021) (0)
HG-20COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA (2016) (0)
EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA (2018) (0)
Abstract LB-137: Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors (2018) (0)
Abstract 1660: Cholesterol efflux transporter gene expression predicts clinical outcome in serous ovarian cancer (2011) (0)
421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancer (2014) (0)
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma (2022) (0)
Abstract 639: Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR (2021) (0)
IL-1ß and TNF- create an immune-metabolic loop regulating Arginase 2 via p38-ERK in neuroblastoma (2019) (0)
Cancer Genes and Genomics c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD 34 þ Hematopoietic Progenitor Cells (2011) (0)
OP0024 Use of novel patient-derived xenografts and molecular subtyping to improve precision medicine in high-grade serous ovarian cancer (2014) (0)
Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions (2022) (0)
Abstract 4869: Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects (2010) (0)
Abstract 888: Reduced folate carrier gene polymorphism (RFC 80G>A): Associations with clinical outcome in NMYC amplified neuroblastoma patients (2010) (0)
differences in biologic characteristics at diagnosis and relapse mouse model of childhood acute lymphoblastic leukemia reveals intrinsic The nonobese diabetic/severe combined immunodeficient (NOD/SCID) (2013) (0)
The MRP 1 / ABCC 1 Multi-drug Transporter Protein and Cancer (2007) (0)
Abstract 617: Small molecule that simultaneously inhibits Myc oncoprotein and activates HIF1A (2011) (0)
MRP4/ABCC4 contributes to the modulation of cAMP in neuroblastoma (2011) (0)
HIGH GRADE GLIOMAS AND DIPG (2014) (0)
PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia (2018) (0)
Improved PCR assay for the detection of antigen receptor gene rearrangements. (1997) (0)
Abstract 3659: Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma (2019) (0)
393 POSTER The multidrug transporter MRP4/ABCC4 is a powerful marker of poor prognosis in neuroblastoma and a target for therapeutic suppression (2006) (0)
DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (2018) (0)
Abstract 3027: SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein (2011) (0)
Genomic landscape of 261 childhood cancer patient-derived xenograft models (2019) (0)
HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG (2021) (0)
The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation (2022) (0)
Abstract 3808: MYCN coordinately regulates the entire polyamine gene pathway to drive polyamine biosynthesis in neuroblastoma, with expression of every synthetic and catabolic polyamine pathway gene being highly prognostic of clinical outcome. (2013) (0)
Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling (2019) (0)
Abstract 1340: Dextran-Catechin conjugate: An anticancer nano-modified natural compound targeting copper metabolism in neuroblastoma (2016) (0)
selection of a preexisting drug-resistant subclone Relapse in children with acute lymphoblastic leukemia involving (2013) (0)

This paper list is powered by the following services:

Other Resources About Michelle Haber

en.wikipedia.org

What Schools Are Affiliated With Michelle Haber?

Michelle Haber is affiliated with the following schools: